Patents by Inventor Glenn Pilkington
Glenn Pilkington has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130022539Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr115 antibodies. The invention encompasses a method of producing the anti-Ovr115 antibodies. Other aspects of the invention are a method of killing an Ovr115-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr115 antibody and a method of alleviating or treating an Ovr115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr115 antibody to the mammal.Type: ApplicationFiled: June 14, 2012Publication date: January 24, 2013Applicant: diaDexus, Inc.Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon
-
Publication number: 20120329079Abstract: A method for assessing risk of prostate cancer utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination is provided. Also provided is a method for assessing risk of cancer utilizing Pro108 or specific antibodies to Pro108. Antibodies that bind to Pro108 on a mammalian cell in vivo and compositions comprising an anti-Pro108 antibody and a carrier which can be provided in an article of manufacture or a kit are also provided. An isolated nucleic acid encoding an anti-Pro108 antibody, an expression vector comprising the isolated nucleic acid, cells that produce the anti-Pro108 antibodies and a method of producing the anti-Pro108 antibodies as well as methods for use of the antibodies in killing an Pro108-expressing cancer cell and alleviating or treating an Pro108-expressing cancer in a mammal are also provided.Type: ApplicationFiled: April 3, 2012Publication date: December 27, 2012Applicant: diaDexus, Inc.Inventors: Iris Simon, Laura Corral, Charis Lawrenson, Nam Kim, Glenn Pilkington, Robert L. Wolfert
-
Publication number: 20120263647Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro104 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro104 antibodies. The invention encompasses a method of producing the anti-Pro104 antibodies. Other aspects of the invention are a method of killing a Pro104-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro104 antibody and a method of alleviating or treating a Pro104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro104 antibody to the mammal.Type: ApplicationFiled: December 16, 2011Publication date: October 18, 2012Applicant: diaDexus, Inc.Inventors: Jackie Papkoff, Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Muriel Kmet, Jianwen Tang
-
Patent number: 8207311Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr115 antibodies. The invention encompasses a method of producing the anti-Ovr115 antibodies. Other aspects of the invention are a method of killing an Ovr115-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr115 antibody and a method of alleviating or treating an Ovr115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr115 antibody to the mammal.Type: GrantFiled: May 17, 2004Date of Patent: June 26, 2012Assignee: diaDexus, Inc.Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon
-
Patent number: 8148093Abstract: This invention relates to a method for assessing risk of prostate cancer. Specifically, it relates to utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In addition, it is directed to a method for assessing risk of ovarian, colon, breast or stomach cancer utilizing Pro108 or specific antibodies to Pro108. The invention provides isolated anti-prostate, ovarian, colon, breast or stomach cancer antigen (Pro108) antibodies that bind to Pro108 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro108 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro108 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro108 antibodies. The invention encompasses a method of producing the anti-Pro108 antibodies.Type: GrantFiled: October 3, 2007Date of Patent: April 3, 2012Assignee: diaDexus, Inc.Inventors: Iris Simon, Laura Corral, Charis Lawrenson, Nam Kim, Glenn Pilkington, Robert L. Wolfert
-
Patent number: 8080650Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro104 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro104 antibodies. The invention encompasses a method of producing the anti-Pro104 antibodies. Other aspects of the invention are a method of killing a Pro104-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro104 antibody and a method of alleviating or treating a Pro104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro104 antibody to the mammal.Type: GrantFiled: January 15, 2009Date of Patent: December 20, 2011Assignee: diaDexus, Inc.Inventors: Jackie Papkoff, Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Muriel Kmet, Jianwen Tang
-
Publication number: 20100209438Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.Type: ApplicationFiled: October 9, 2009Publication date: August 19, 2010Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Jackie Papkoff
-
Patent number: 7619068Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.Type: GrantFiled: May 10, 2004Date of Patent: November 17, 2009Assignee: diaDexus, Inc.Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Jackie Papkoff
-
Publication number: 20090232732Abstract: This invention relates to a method for assessing risk of prostate cancer. Specifically, it relates to utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In addition, it is directed to a method for assessing risk of ovarian, colon, breast or stomach cancer utilizing Pro108 or specific antibodies to Pro108. The invention provides isolated anti-prostate, ovarian, colon, breast or stomach cancer antigen (Pro108) antibodies that bind to Pro108 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro108 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro108 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro108 antibodies. The invention encompasses a method of producing the anti-Pro108 antibodies.Type: ApplicationFiled: October 3, 2007Publication date: September 17, 2009Inventors: IRIS SIMON, LAURA CORRAL, CHARIS LAWRENSON, NAM KIM, GLENN PILKINGTON, ROBERT L. WOLFERT
-
Publication number: 20090220424Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro104 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro104 antibodies. The invention encompasses a method of producing the anti-Pro104 antibodies. Other aspects of the invention are a method of killing a Pro104-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro104 antibody and a method of alleviating or treating a Pro104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro104 antibody to the mammal.Type: ApplicationFiled: January 15, 2009Publication date: September 3, 2009Inventors: Jackie Papkoff, Glenn Pilkington, Gilbert-Andre Keller, Weniu Li, Laura Corral, Iris Simon, Muriel Kmet, Jianwen Tang
-
Publication number: 20090136490Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110 expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.Type: ApplicationFiled: November 10, 2005Publication date: May 28, 2009Applicant: DIADEXUS, INC.Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Timothy S. Burcham, Laura Corral, Iris Simon, Jackie Papkoff
-
Patent number: 7479546Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro 104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro 104 antibody, as well as an expression vector comprising the isolated'l nucleic acid. Also provided are cells that produce the anti-Pro 104 antibodies. The invention encompasses a method of producing the anti-Pro 104 antibodies. Other aspects of the invention are a method of killing a Pro 104-expressing cancer cell, comprising contacting the cancer cell with an antiPro104 antibody and a method of alleviating or treating a Pro 104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro 104 antibody to the mammal.Type: GrantFiled: June 28, 2004Date of Patent: January 20, 2009Assignee: diaDexus, Inc.Inventors: Jackie Papkoff, Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Muriel Kmet, Jianwen Tang
-
Publication number: 20070292346Abstract: This invention relates to a method for assessing risk of lung and/or breast cancer. Specifically, in one embodiment it relates to utilizing Lng105 to determine the risk of lung cancer. Specific antibodies are disclosed.Type: ApplicationFiled: March 25, 2005Publication date: December 20, 2007Inventors: Rong Fan, Nam Kim, Robert Wolfert, Glenn Pilkington
-
Patent number: 7294704Abstract: This invention relates to a method for assessing risk of prostate cancer. Specifically, it relates to utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In addition, it is directed to a method for assessing risk of ovarian, colon, breast or stomach cancer utilizing Pro108 or specific antibodies to Pro108. The invention provides isolated anti-prostate, ovarian, colon, breast or stomach cancer antigen (Pro108) antibodies that bind to Pro108 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro108 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro108 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro108 antibodies. The invention encompasses a method of producing the anti-Pro108 antibodies.Type: GrantFiled: August 16, 2004Date of Patent: November 13, 2007Assignee: diaDexus, Inc.Inventors: Iris Simon, Laura Corral, Charis Lawrenson, Nam Kim, Glenn Pilkington, Robert L. Wolfert
-
Publication number: 20070178101Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.Type: ApplicationFiled: May 10, 2004Publication date: August 2, 2007Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Jackie Papkoff
-
Publication number: 20070104647Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr115 antibodies. The invention encompasses a method of producing the anti-Ovr115 antibodies. Other aspects of the invention are a method of killing an Ovr115-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr115 antibody and a method of alleviating or treating an Ovr115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr115 antibody to the mammal.Type: ApplicationFiled: May 17, 2004Publication date: May 10, 2007Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon
-
Publication number: 20070087004Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro 104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro 104 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro 104 antibodies. The invention encompasses a method of producing the anti-Pro 104 antibodies. Other aspects of the invention are a method of killing a Pro 104-expressing cancer cell, comprising contacting the cancer cell with an antiPro104 antibody and a method of alleviating or treating a Pro 104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pr 104 antibody to the mammal.Type: ApplicationFiled: June 28, 2004Publication date: April 19, 2007Inventors: Jackie Papkoff, Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral
-
Publication number: 20050124012Abstract: This invention relates to a method for assessing risk of prostate cancer. Specifically, it relates to utilizing both Pro108 and Prostate Specific Antigen (PSA) in combination to determine the risk of prostate cancer. In addition, it is directed to a method for assessing risk of ovarian, colon, breast or stomach cancer utilizing Pro108 or specific antibodies to Pro108. The invention provides isolated anti-prostate, ovarian, colon, breast or stomach cancer antigen (Pro108) antibodies that bind to Pro108 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro108 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro108 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro108 antibodies. The invention encompasses a method of producing the anti-Pro108 antibodies.Type: ApplicationFiled: August 16, 2004Publication date: June 9, 2005Inventors: Iris Simon, Laura Corral, Charis Lawrenson, Nam Kim, Glenn Pilkington, Robert Wolfert